Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to collect health economic data depicting the initial
levels and natural progression over time of resource usage, Parkinson's disease (PD)-related
costs, and health related quality of life (HRQoL) for a cohort of advanced PD patients
treated with Duodopa (levodopa-carbidopa in an intestinal gel formulation), of which about
one-third were Duodopa-naïve prior to the start of the study.
Phase:
Phase 4
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa